globulina antilinfocítica en el tratamiento de la anemia aplásica severa

Clicks: 8
ID: 246370
1999
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #63 of 74 articles by views in shs web of conferences

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Objetivo: Describir la experiencia en nuestro hospital en el tratamiento de anemia aplásica severa con globulina antilinfocítica. Materiales y Metodos: Se estudiaron 58 pacientes con AAS diagnosticados entre 1988-1998 de los cuales 25 recibieron Globulina antilinfocítica (GAL), 56% de ellos eran menores a 20 años de edad,19 de los pacientes tratados con GAL son del sexo masculino . Resultado: Respondieron favorablemente 68%(17pacientes),la mayoría de ellos (64%)alcanzaron esta respuesta durante los primeros 6 meses. Un paciente evolucionó a Hemoglobinuria paroxística nocturna (HPN), efectos adversos fueron leves y de corta duración. (Rev Med Hered;1999 ;10:132 - 136 ).
Reference Key
perez1999revistaglobulina Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Víctor Ulloa Perez;Wilson Ruiz Gil;Luz Bustamante;Carolina Tokumura Tokumura
Journal shs web of conferences
Year 1999
DOI
DOI not found
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.